Charles Guy Theillet

List of Publications by Year
in descending order

93 papers	7,266 citations	66343 42 h-index	58581 82 g-index
101 all docs	101 docs citations	101 times ranked	9959 citing authors

#	Article	IF	Citations
1	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. Clinical Cancer Research, 2006, 12, 1157-1167.	7.0	495
2	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nature Cell Biology, 2009, 11, 1315-1324.	10.3	445
3	EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer. Cell, 2003, 115, 523-535.	28.9	389
4	Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4834-4838.	7.1	374
5	Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science, 1987, 238, 185-188.	12.6	294
6	Snail and Slug Play Distinct Roles during Breast Carcinoma Progression. Clinical Cancer Research, 2006, 12, 5395-5402.	7.0	230
7	A refined molecular taxonomy of breast cancer. Oncogene, 2012, 31, 1196-1206.	5.9	221
8	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. Molecular Cancer Research, 2005, 3, 655-667.	3.4	201
9	A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clinical Cancer Research, 2008, 14, 1744-1752.	7.0	164
10	Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13351-13356.	7.1	161
11	FGFRI andPLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers. Genes Chromosomes and Cancer, 1993, 7, 219-226.	2.8	158
12	Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection ofcyclin D1 in breast andcyclin E in ovarian tumors. , 1996, 69, 247-253.		158
13	TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes and Cancer, 1995, 14, 71-75.	2.8	154
14	Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 207-216.	4.4	154
15	Protocols for an improved detection of point mutations by SSCP. Nucleic Acids Research, 1991, 19, 4009-4009.	14.5	148
16	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clinical Cancer Research, 2016, 22, 3067-3077.	7.0	144
17	Detailed map of a region commonly amplified at 11q13â†’q14 in human breast carcinoma. Cytogenetic and Genome Research, 1997, 79, 125-131.	1.1	135
18	Predominant occurrence of somatic mutations of theNF2 gene in meningiomas and schwannomas. Genes Chromosomes and Cancer, 1995, 13, 211-216.	2.8	132

#	Article	IF	Citations
19	miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene, 2010, 29, 4436-4448.	5.9	119
20	Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene, 2008, 27, 5359-5372.	5.9	107
21	High Frequency of Rare Alleles of the Human c-Ha-ras-1 Proto-oncogene in Breast Cancer Patients2. Journal of the National Cancer Institute, 1986, 77, 697-701.	6.3	97
22	p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. British Journal of Cancer, 1994, 69, 846-852.	6.4	96
23	Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene, 1999, 18, 3979-3988.	5.9	90
24	Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. Journal of Molecular Endocrinology, 2004, 32, 397-414.	2.5	86
25	Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes and Cancer, 1994, 9, 42-48.	2.8	85
26	DNA amplification at 11q13 in human cancer: from complexity to perplexity. Mutation Research - Reviews in Genetic Toxicology, 1992, 276, 317-328.	2.9	84
27	Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes. Cancer Research, 2004, 64, 6453-6460.	0.9	83
28	Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research, 2017, 23, 2806-2816.	7.0	82
29	Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer, 2003, 3, 13.	2.6	77
30	Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. British Journal of Cancer, 2006, 95, 1439-1447.	6.4	77
31	Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. European Journal of Cancer & Clinical Oncology, 1990, 26, 437-441.	0.7	76
32	Prognostic Significance of TRIM24/TIF-1Î± Gene Expression in Breast Cancer. American Journal of Pathology, 2011, 178, 1461-1469.	3.8	73
33	Patterns of allele losses suggest the existence of five distinct regions of loh on chromosome 17 in breast cancer. International Journal of Cancer, 1994, 56, 193-199.	5.1	66
34	Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. International Journal of Cancer, 2002, 100, 557-564.	5.1	64
35	MIR@NT@N: a framework integrating transcription factors, microRNAs and their targets to identify sub-network motifs in a meta-regulation network model. BMC Bioinformatics, 2011, 12, 67.	2.6	64
36	Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29.		63

#	Article	IF	Citations
37	Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome. Clinical Cancer Research, 2004, 10, 5785-5791.	7.0	62
38	Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene, 1997, 14, 339-347.	5.9	60
39	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes and Cancer, 2003, 37, 333-345.	2.8	56
40	17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene, 1999, 18, 6262-6270.	5.9	55
41	ras, p53 and hpv status in benign and malignant prostate tumors. International Journal of Cancer, 1995, 64, 124-129.	5.1	51
42	At least five regions of imbalance on 6q in breast tumors, combining losses and gains. , 2000, 27, 76-84.		49
43	CD44 expression patterns in breast and colon tumors: A pcr-based study of splice variants. International Journal of Cancer, 1995, 64, 347-354.	5.1	48
44	CCND1 andFGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. , 1998, 22, 268-277.		48
45	Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Molecular Oncology, 2014, 8, 431-443.	4.6	48
46	Direct sequencing by thermal asymmetric PCR. Nucleic Acids Research, 1991, 19, 4783-4783.	14.5	47
47	Influence of the excision shock on the protein metabolism ofVicia faba L. meristematic root cells. Planta, 1982, 155, 478-485.	3.2	45
48	HumanE2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Genes Chromosomes and Cancer, 2000, 28, 126-130.	2.8	44
49	MYEOV: A candidate gene for DNA amplification events occurring centromeric toCCND1in breast cancer. International Journal of Cancer, 2002, 102, 608-614.	5.1	44
50	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget, 2017, 8, 106415-106428.	1.8	42
51	A predictable conserved DNA base composition signature defines human core DNA replication origins. Nature Communications, 2020, 11, 4826.	12.8	41
52	Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7068-7070.	7.1	40
53	Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. Molecular BioSystems, 2012, 8, 3242.	2.9	40
54	Gradual Selection of a Cellular Clone Presenting a Mutation at Codon 179 of the p53 Gene during Establishment of the Immortalized Human Breast Epithelial Cell Line HMT-3522. Experimental Cell Research, 1994, 215, 380-385.	2.6	37

#	Article	IF	Citations
55	TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion. Nature Communications, 2016, 7, 10765.	12.8	37
56	Two Human Genes Related to Murine Vanin-1 Are Located on the Long Arm of Human Chromosome 6. Genomics, 1998, 53, 203-213.	2.9	35
57	Impact of chromosomal instability on colorectal cancer progression and outcome. BMC Cancer, 2014, 14, 121.	2.6	35
58	An auristatinâ€based antibodyâ€drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. International Journal of Cancer, 2019, 145, 1838-1851.	5.1	33
59	Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget, 2015, 6, 28084-28103.	1.8	32
60	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632.	7.0	31
61	Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets theFHITgene. Genes Chromosomes and Cancer, 2002, 35, 204-218.	2.8	30
62	Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB Journal, 2006, 20, 240-250.	0.5	30
63	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Critical Reviews in Oncology/Hematology, 2019, 133, 58-73.	4.4	30
64	CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Letters, 2000, 156, 45-50.	7.2	28
65	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers, 2020, 12, 828.	3.7	27
66	Localization of 11q13 loci with respect to regional chromosomal breakpoints. Genomics, 1992, 12, 738-744.	2.9	24
67	Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget, 2015, 6, 28327-28340.	1.8	24
68	Structure and Chromosomal Assignment to 22q12 and 17qter of the ras-Related Rac2 and Rac3 Human Genes. Genomics, 1997, 44, 242-246.	2.9	23
69	Full speed ahead for tumor screening. Nature Medicine, 1998, 4, 767-768.	30.7	23
70	Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-typep53. Molecular Carcinogenesis, 1998, 23, 1-12.	2.7	23
71	Stable amino-acid sequence of the Mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines. International Journal of Cancer, 2000, 85, 466-473.	5.1	23
72	Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Letters, 2000, 154, 9-17.	7.2	20

#	Article	IF	Citations
73	In situ detection of c-myc mRNA in adenocarcinomas, adenomas, and mucosa of human colon.. Journal of Histochemistry and Cytochemistry, 1989, 37, 293-298.	2.5	19
74	Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma. Oncogene, 2018, 37, 578-588.	5.9	18
75	Genetic variability of proto-oncogenes for breast cancer risk and prognosis. Biochimie, 1988, 70, 951-959.	2.6	17
76	Mutation of the Tumor Suppressor Gene TP53 Is Not Detected in Psoriatic Skin. Journal of Investigative Dermatology, 1993, 101, 100-102.	0.7	17
77	A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer, 2007, 7, 39.	2.6	17
78	D11S146 and BCL1 are physically linked but can be discriminated by their amplification status in human breast cancer. Genomics, 1991, 10, 410-416.	2.9	16
79	An attempt to define sets of cooperating genetic alterations in human breast cancer. International Journal of Cancer, 1992, 51, 542-547.	5.1	15
80	Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyondBRCA1/2mutations?. Future Oncology, 2015, 11, 557-559.	2.4	15
81	Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease. FEBS Letters, 1994, 341, 156-161.	2.8	14
82	Human gp130 transducer chain gene (IL6ST) is localized to chromosome band 5q11 and possesses a pseudogene on chromosome band 17p11. Cytogenetic and Genome Research, 1995, 70, 64-67.	1.1	14
83	An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Medical Genomics, 2012, 5, 54.	1.5	14
84	Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. Oncotarget, 2017, 8, 95206-95222.	1.8	14
85	Role of FGFs and FGF Receptors in Human Carcinogenesis. Annals of the New York Academy of Sciences, 1991, 638, 409-411.	3.8	12
86	Involvement ofATMmissense variants and mutations in a series of unselected breast cancer cases. Genes Chromosomes and Cancer, 2002, 33, 141-149.	2.8	11
87	In highâ€grade ovarian carcinoma, platinumâ€sensitive tumor recurrence and acquiredâ€resistance derive from quiescent residual cancer cells that overexpress <scp>CRYAB</scp>, <scp>CEACAM6,</scp> and <scp>SOX2</scp>. Journal of Pathology, 2022, 257, 367-378.	4.5	11
88	What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Research, 2010, 12, 107.	5.0	10
89	Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. International Journal of Cancer, 2019, 145, 1299-1311.	5.1	6
90	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs, 2021, 13, 1914883.	5.2	4

#	Article	IF	Citations
91	105 The 11q13 region in human tumors. Cancer Genetics and Cytogenetics, 1989, 38, 192.	1.0	1
92	Impact of genomic instability in colorectal cancers. Cancer Genetics and Cytogenetics, 2010, 203, 92.	1.0	0
93	Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry. International Journal of Molecular Sciences, 2022, 23, 5701.	4.1	0